Don’t miss the aesthetics event of the year. Register today for Wigmore Presents on 20th and 21st April to access a wealth of knowledge from industry-leading speakers, and discover new approaches and techniques to take your aesthetics business to new heights.
Here are three must-attend talks scheduled for this year’s conference...
1. Regenerative medicine - an update
Explore the latest advancements in regenerative medicine. Join world-leading experts to discuss the potential of combination therapies and their impact on enhancing patient outcomes in this rapidly evolving field.
Speakers: Prof Syed Haq, Dr Aamer Khan, Dr Sherina Balaratnam, Dr Neal Kitchen, Dr Abs Settipalli, Dr Nestor Demosthenous and Professor Alan Widgerow
2. Are we using a Ferrari to deliver bread? Are we ignoring new technologies?
New technology is key to evolving aesthetic practice. However, integration into longstanding clinic offerings can be challenging as we strive to understand how to optimise patient care and outcomes. Emerging new technologies can take our approach to aesthetic medicine to the next level, including:
- DNA analysis to guide personalised treatment planning
- Regeneration at a cellular level
- Aesthetic outcomes from within: nutrition, supplementation specific to healthy ageing and wearable technology to optimise lifestyle factors, like blood sugar management
Speaker: Dr Anna Hemming
3. The middle-aged male face: an increasingly relevant challenge
More men are seeking aesthetic treatments to enhance their self-image as they age. This session addresses the growing trends and challenges in treating the male face, offering insights into treatment placement, best practices, and patient management.
Speakers: Dr Emma Ravichandran and Dr Raj Thethi
Tickets can be purchased now via the website wigmorepresents.com - it is £150 for a one-day pass and £250 for two days.
The pass includes access to the agenda*, exhibition, refreshments and lunch. The Saturday networking event can be purchased separately for £75.
*Some lectures will only be accessible to HCPs.
